Starling Oncology forecasts FY2026 revenue of $650-670 million

Reuters2026/09/09 10:38

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Starling Oncology forecast FY26 revenue of USD 650-670 million, based on guidance reiterated in its Aug. 6, 2026 2Q26 release.
Adjusted EBITDA expected at USD 2-7 million for FY26, implying a low single-digit margin on the revenue outlook.
Forecast follows FY25 revenue of USD 503 million, with revenue mix led by specialty pharmacy at 54%.
Growth backdrop includes 2.3 million value-based care lives under contract, 60+ payor contracts, 300,000+ encounters in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Starling Oncology Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Starling Oncology forecasts FY2026 revenue of $650-670 million

You may also like

Crypto prices